Pre-Commercial Value Assessment of a Nuclear Medicine Pair to Diagnose and Treat Neuroendocrine Tumors (NET)

Publications
Category:
Published on:
August 1, 2020
Written by:
Piergiulio Lauriano

When our client, a leading radiopharmaceutical company, needed support to understand the commercial opportunity represented by a Phase III radiopharmaceutical and its diagnostic radiotracer companion, Alira Health stepped in to run a comprehensive analysis.

Read on to learn how our team analyzed the market, assessed value assets, and helped our client move forward with confidence.

For more information, please contact Piergiulio Lauriano.

For more information about Alira Health’s Management Consulting services

Click here

Related news

Publications May 25, 2023
The EU Pharmaceutical Package: Introduction to Changes
Alira Health’s Regulatory experts explore how the proposed package will disrupt the European regulatory landscape and what it means for companies.
EU Pharma Regulatory
Events May 16, 2023
PSI 2023 Conference
We're excited to talk orphan drugs and rare diseases at the World Orphan Drug Congress in Washington, D.C.
Orphan Drug Pharma Rare Disease UK
Events May 15, 2023
World Orphan Drug Congress USA
We're excited to talk orphan drugs and rare diseases at the World Orphan Drug Congress in Washington, D.C.
Orphan Drug Pharma Rare Disease
Events May 15, 2023
BIO International Convention
We are excited to share that we will be attending the BIO International Convention in Boston. This leading industry event attracts biotechnology and pharma leaders for one week of intensive(...)
Biotech Pharma
Blog April 17, 2023
Reimbursement of Rare Disease Drugs in Italy: Challenges and Hopes for the Future
When it comes to rare diseases, Italy has done a good job in bringing EMA-approved drugs, including orphan drugs, to the Italian market. But  multiple challenges exist, many of which(...)
Italy Market Access Pharma Rare Disease Real-World Evidence (RWE)
Blog April 17, 2023
Pharmaceutical Market Access in the UK: A Changing Landscape
Start reading this interview with Rachel Fyson to gain insight into the changing landscape of market access in the United Kingdom.
Market Access Pharma UK
Blog April 14, 2023
Lifecycle Optimization: The Path to Commercial Success
Pharmaceutical and biotech companies constantly focus on product innovation. But how can you also increase your effectiveness in order to be as commercially competitive and efficient as possible?
Market Access MedTech Pharma
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.